Mankind Pharma on Thursday reported a 17.4% year-on-year decline in net profit for the quarter ended June 30, 2025, despite a robust 24.5% growth in revenue, as higher costs and margin pressures weighed on bottom-line performance.
Profit after tax stood at Rs 445 crore, down from Rs 538 crore in Q1FY25. The company’s EBITDA rose 25.8% to Rs 850 crore, with margins improving slightly to 23.8%.
Revenue from operations surged to Rs 3,570 crore, driven by strong growth in both domestic and export businesses. Domestic sales rose 18.9% to Rs 3,101 crore, while exports jumped 81.1% to Rs 469 crore, aided by the consolidation of BSV and expansion in the base business.
“We continue to outperform the Indian pharma market across chronic and acute segments,” said Rajeev Juneja, Vice Chairman and Managing Director. “Our consumer healthcare and specialty portfolios are gaining traction, and we remain confident of delivering healthy performance this year onwards.”
Consumer Healthcare (CH) revenue grew 15% YoY to Rs 237 crore, with strong secondary sales in brands like Gas-O-Fast, Manforce, and Preganews.
Domestic Business (ex-CH) grew 19.2% YoY to Rs 2,864 crore, led by chronic therapies such as cardiology and anti-diabetics. Export business saw an 81% YoY rise, though it declined 12.3% sequentially. Gross margins stood at 70.5%, down 130 basis points YoY.
Net debt to EBITDA ratio was 1.6x, with net debt at Rs 5,249 crore.
The company also approved an interim dividend of Re 1 per share to mark its 30-year milestone.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
